Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Change in Account Payables (2016 - 2025)

Standard Biotools (LAB) has disclosed Change in Account Payables for 16 consecutive years, with $946000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables rose 143.14% to $946000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.7 million, a 115.73% increase, with the full-year FY2024 number at -$13.0 million, down 901.92% from a year prior.
  • Change in Account Payables was $946000.0 for Q3 2025 at Standard Biotools, down from $1.4 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.4 million in Q1 2021 to a low of -$10.3 million in Q1 2024.
  • A 5-year average of -$582526.3 and a median of -$131000.0 in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: tumbled 12266.67% in 2021, then surged 511.37% in 2023.
  • Standard Biotools' Change in Account Payables stood at -$131000.0 in 2021, then crashed by 873.28% to -$1.3 million in 2022, then surged by 264.86% to $2.1 million in 2023, then crashed by 104.19% to -$88000.0 in 2024, then skyrocketed by 1175.0% to $946000.0 in 2025.
  • Per Business Quant, the three most recent readings for LAB's Change in Account Payables are $946000.0 (Q3 2025), $1.4 million (Q2 2025), and -$578000.0 (Q1 2025).